Dermata Therapeutics Inc (DRMA)
Dermata Therapeutics, Inc. is a late-stage medical dermatology company focused on developing and commercializing pharmaceutical candidates for medical skin diseases and certain aesthetic applications. Its lead program, XYNGARI, is being evaluated in Phase 3 studies for moderate-to-severe acne and has also completed a Phase 1b proof-of-concept trial in mild-to-moderate psoriasis. The company is also advancing DMT410, which has completed Phase 1b proof-of-concept trials for axillary hyperhidrosis and aesthetic skin conditions. Dermata has a clinical trial collaboration with Revance Therapeutics to assess topical XYNGARI in combination with DAXXIFY, Revance’s botulinum toxin type A product. Dermata Therapeutics was incorporated in 2014 and is headquartered in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DRMA
|
$1.82
|
46.8% Upside
|
Undervalued
|
$4
|
222.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.7x
|
0.8x
|
—
|
5.108 M
|
-1.978 M
|
0.0%
|
78.8%
|
-24.1
|
—
|
116.9%
|
